Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden

Table 2 Outcomes of patients receiving SOC or CCP

	SOC (n = 14)	CCP (n = 17)	Effect size	p-value
Time of oxygen treatment, days^e	7 (5–9)^a	11 (6–15)^a	−4^c	0.43
Length of stay, days	8 (6–10)^a	13 (7–16)^a	−5^c	0.21
Progression to HFNC^f	4/13 (31)^b	4/16 (25)^b	0.75 (0.18–3.18)^d	> 0.99
Progression to ventilator treatment	1 (7)^b	0^b	0 (0–7.41)^d	0.45
Death	3 (21)^b	2 (12)^b	0.49 (0.08–2.79)^d	0.64

^aMedian (IQR). ^bNumbers (%). ^cMedian difference. ^dOdds ratio (CI).^eFor patients surviving 28-days. ^fOne patient in each group with ongoing HFNC on inclusion was excluded from the analysis

ISSN: 1756-0500